ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3003

Impact of Preoperative Opioid Use on Total Knee Arthroplasty Outcomes

Savannah R. Smith1, Heidi Y. Yang2, Jamie E. Collins3, Jeffrey N. Katz4 and Elena Losina5, 1Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 2Orthopaedic and Arthritis Center for Outcomes Research, Brigham & Women's Hospital, Boston, MA, 3Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, 4Orthopaedics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Orthopaedics, Brigham & Women's Hospital, Boston, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: opioids, osteoarthritis and outcomes, Total Knee Arthroplasty (TKA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Orthopedics, Low Back Pain and Rehabilitation

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Total knee arthroplasty (TKA) is an effective treatment for patients with end-stage knee osteoarthritis (OA); however, a growing body of evidence suggests that patients using opioids prior to TKA experience worse pain outcomes immediately following surgery. We evaluated the pain relief achieved from TKA in knee OA patients with and without opioid prescriptions pre-TKA.

Methods: We augmented patient-reported data from a longitudinal study of TKA outcomes with medical record-based information about opioid use. The study included patients >40 years old who underwent primary, unilateral TKA at a tertiary academic medical center. The Pain Catastrophizing Scale (PCS) and patient-reported outcomes, including the Western Ontario and McMaster Universities Arthritis Index (WOMAC), were assessed at baseline and 6 months post-TKA. Demographic and comorbidity information were collected at baseline via study questionnaire. We reviewed the electronic medical record of each subject to identify opioid use from two years pre- to one year post-TKA. We documented the dates of first and last opioid prescription and any additional surgeries done during the study period. We restricted our analyses to those who did not have additional surgery during the study period and who had no more than 2 comorbidities. To address confounding by indication we built a propensity score of opioid use based on age, PCS, comorbidities, and pain prior to TKA. The propensity score ranged from 10% to 75% likelihood of opioid use. The primary analysis included subjects with propensity scores from 20-75%. We compared WOMAC Pain scores (0-100, 100 worst) at 6 months after TKA in persons without opioid use to those with documented pre-TKA opioid use with a general linear model, adjusting for propensity score, PCS, and baseline pain.

Results: Our analytic cohort consisted of 134 patients with mean age 68 years (SD 8); 66% were female and mean pre-TKA WOMAC Pain was 43 (SD 16). Nineteen percent had at least one opioid prescription prior to TKA. Baseline WOMAC Pain scores were higher among those who used opioids pre-TKA (49 vs. 41, p=0.04). PCS was substantially greater among pre-TKA opioid users (18 vs. 12, p=0.004). Adjusted analyses showed that the opioid group had mean 6-month WOMAC pain of 18 points, while the non-opioid group had mean WOMAC Pain of 10 points (p = 0.0017). The adjusted difference in pain from pre-TKA to 6 month post-TKA was estimated at 25 WOMAC points among those who use opioids prior to TKR compared to 33 WOMAC points among those who did not use opioids (p=0.0017).

Conclusion: Patients with pre-TKA opioid use had higher levels of pain catastrophizing and WOMAC Pain at baseline, and, after adjusting for differences in baseline pain, pain catastrophizing, and likelihood of opioid use, had higher pain 6 months after TKA compared to patients without preoperative opioid use. With the substantial societal burden associated with opioid use, clinicians and policymakers may consider limiting the use of these analgesics prior to TKA to optimize the efficacy of the procedure.


Disclosure: S. R. Smith, None; H. Y. Yang, None; J. E. Collins, None; J. N. Katz, None; E. Losina, None.

To cite this abstract in AMA style:

Smith SR, Yang HY, Collins JE, Katz JN, Losina E. Impact of Preoperative Opioid Use on Total Knee Arthroplasty Outcomes [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/impact-of-preoperative-opioid-use-on-total-knee-arthroplasty-outcomes/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-preoperative-opioid-use-on-total-knee-arthroplasty-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology